Pharmaceutical Technology on MSN

Eli Lilly outlays $1.12BN for hearing loss gene therapy partnership

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.
Stocktwits on MSN

Eli Lilly strikes $1.1 billion deal with Seamless Therapeutics to develop gene therapies for hearing loss

Seamless will receive over $1.1 billion, which also includes potential milestone payments for achieving development and ...

Eli Lilly Uses GLP 1 Strength To Build Broader Drug Pipeline

Eli Lilly (NYSE:LLY) plans to invest over US$3.5b in a new Pennsylvania manufacturing facility focused on next generation ...
BioPharma Dive

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss

Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient ...
Frontiers

Hearing Loss & Cognitive Decline: Mechanisms, Interventions, and Prevention

BackgroundHearing loss is among the most prevalent and potentially modifiable risk factors for dementia across the life course. Beyond reduced audibility, ...